Biogen presented Phase 2 CELIA trial results for diranersen, an antisense oligonucleotide targeting tau, in early Alzheimer’s disease at the AAIC meeting. The data indicated slowing of cognitive decline at rates comparable to approved anti-amyloid therapies. A separate preclinical study showed a repurposed compound already proven safe in humans reduced Alzheimer’s markers in mice.
Biogen’s tau-targeting data arrives amid skepticism over high prices and modest gains of existing Alzheimer’s therapies, highlighting risks of restricted access for lower-income and minority patients.
“Equity concerns and corporate priorities versus public-health outcomes”
Private-sector innovation demonstrated measurable benefit in early-stage patients, aligning with market-driven solutions that may reduce long-term Medicare and caregiver costs.
“Value of biotech progress without expansive government programs”
Market incentives and voluntary investment expand treatment options, supporting maximum patient choice and right-to-try access based on emerging evidence.
“Individual autonomy over centralized regulatory gatekeeping”
All perspectives accept the parity claim at face value while overlooking marginal effect patterns in Alzheimer’s trials, the unrelated nature of the mouse compound, and the preliminary AAIC format.
“Shared omission of mechanistic uncertainty and historical trial limitations”